3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1217
Neoplasms
1033
Carcinoma, Non-Small-Cell Lung
747
Prostatic Neoplasms
688
Colorectal Neoplasms
593
Lung Neoplasms
575
Pancreatic Neoplasms
407
Leukemia, Myeloid, Acute
396
Neoplasm Metastasis
382
Multiple Myeloma
373
Ovarian Neoplasms
369
Stomach Neoplasms
322
Carcinoma, Hepatocellular
301
Recurrence
281
Melanoma
281
Brain Neoplasms
274
Squamous Cell Carcinoma of Head and Neck
269
Endometrial Neoplasms
234
Head and Neck Neoplasms
232
Triple Negative Breast Neoplasms
231
Precursor Cell Lymphoblastic Leukemia-Lymphoma
227
Lymphoma
227
Glioblastoma
225
Uterine Cervical Neoplasms
222
Sarcoma
201
Hematologic Neoplasms
201
Urinary Bladder Neoplasms
196
Esophageal Neoplasms
192
Carcinoma, Renal Cell
190
Lymphoma, Non-Hodgkin
176
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
High-Risk Localized Prostate Cancer
×
1 year
×
Clear all
NCT07450599
2026-05-13
CHINANEO
Bayer
Phase 2
Recruiting
250 enrolled